Subscribe

Laboratorio Reig Jofre, S.A. (RJF.MC)

EUR2.65 +0.00 (+0.00%)
ES BME Healthcare Drug Manufacturers - Specialty & Generic
Address Gran Capita, 10 8970
Barcelona, ES
CEO Ignasi Biosca Reig
Website reigjofre.com
IPO 2002-11-29
ISIN ES0165359029

Explore sections of this company profile

Description

Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR2.65 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10.2K
Beta
0.96
Float Shares
17.32M
Free Float %
21.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.09% +1.11% +2.25% +5.00% +1.49% +6.23% -16.77% +4.20% -47.90% -6.83% -91.78%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2.65
DCF (Unlevered) 2.83 +6.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.72
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -2.3% Q1'26: -1.9% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -52.5% Q1'26: -17.9% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -0.7% Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +1.7% Q1'26: +4.3% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +1.5% Q1'26: +4.9% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +1.7% Q1'26: +1.7% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    3.23× Q1'26: 2.53× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.95) × ERP
WACC = 69% × Ke + 31% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 2.83 Current price: 2.65
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
156.91M
est: 157.02M (-0.1%)
161.13M
est: 164.59M (-2.1%)
167.98M
est: 176.40M (-4.8%)
180.47M
est: 180.10M (+0.2%)
200.21M
est: 203.00M (-1.4%)
230.08M
est: 230.00M (+0.0%)
236.23M
est: 230.00M (+2.7%)
271.15M
est: 264.00M (+2.7%)
316.09M
est: 324.00M (-2.4%)
338.90M
est: 346.80M (-2.3%)
331.10M
est: 327.35M (+1.1%)
358.95M
358.95M – 358.95M
+9.7% YoY
388.45M
388.45M – 388.45M
+8.2% YoY
416.95M
416.95M – 416.95M
+7.3% YoY
EBITDA
17.53M
est: 16.84M (+4.1%)
19.15M
est: 17.65M (+8.4%)
15.78M
est: 18.92M (-16.6%)
17.70M
est: 19.32M (-8.4%)
19.12M
est: 21.77M (-12.2%)
24.31M
est: 24.67M (-1.5%)
24.66M
est: 24.67M (0.0%)
30.44M
est: 28.32M (+7.5%)
33.89M
est: 34.75M (-2.5%)
36.18M
est: 36.25M (-0.2%)
30.48M
est: 34.22M (-10.9%)
37.53M
37.53M – 37.53M
+9.7% YoY
40.61M
40.61M – 40.61M
+8.2% YoY
43.59M
43.59M – 43.59M
+7.3% YoY
EBIT
11.65M
est: 5.22M (+123.2%)
12.57M
est: 5.47M (+129.7%)
8.72M
est: 5.87M (+48.6%)
10.10M
est: 5.99M (+68.6%)
5.97M
est: 6.75M (-11.5%)
7.33M
est: 7.65M (-4.2%)
6.61M
est: 7.65M (-13.5%)
9.37M
est: 8.78M (+6.8%)
10.75M
est: 10.77M (-0.2%)
12.83M
est: 10.52M (+22.0%)
5.70M
est: 9.93M (-42.6%)
10.88M
10.88M – 10.88M
+9.7% YoY
11.78M
11.78M – 11.78M
+8.2% YoY
12.64M
12.64M – 12.64M
+7.3% YoY
Net Income
8.75M
est: 11.40M (-23.3%)
7.68M
est: 8.32M (-7.7%)
8.83M
est: 11.13M (-20.7%)
9.27M
est: 8.81M (+5.2%)
4.94M
est: 7.21M (-31.4%)
5.67M
est: 11.21M (-49.4%)
5.09M
est: 8.81M (-42.2%)
8.11M
est: 9.61M (-15.6%)
9.41M
est: 13.61M (-30.9%)
10.38M
est: 13.43M (-22.7%)
5.02M
est: 4.48M (+12.2%)
11.39M
11.39M – 11.39M
+154.5% YoY
11.80M
11.80M – 11.80M
+3.6% YoY
16.28M
16.28M – 16.28M
+37.9% YoY
SGA
15.69M
est: 13.52M (+16.0%)
16.81M
est: 14.17M (+18.6%)
14.31M
est: 15.19M (-5.8%)
15.31M
est: 15.51M (-1.3%)
20.30M
est: 17.48M (+16.1%)
16.81M
est: 19.80M (-15.1%)
18.24M
est: 19.80M (-7.9%)
35.30M
est: 22.73M (+55.3%)
22.69M
est: 27.90M (-18.7%)
26.54M
est: 35.37M (-25.0%)
50.48M
est: 33.39M (+51.2%)
36.61M
36.61M – 36.61M
+9.7% YoY
39.62M
39.62M – 39.62M
+8.2% YoY
42.52M
42.52M – 42.52M
+7.3% YoY
EPS
0.14
est: 0.14 (-1.7%)
0.12
est: 0.10 (+15.5%)
0.14
est: 0.14 (+0.7%)
0.14
est: 0.11 (+27.3%)
0.07
est: 0.09 (-23.0%)
0.07
est: 0.14 (-46.9%)
0.07
est: 0.11 (-39.8%)
0.10
est: 0.12 (-16.7%)
0.12
est: 0.17 (-29.4%)
0.13
est: 0.17 (-21.2%)
0.06
est: 0.06 (+12.2%)
0.14
0.14 – 0.14
+154.5% YoY
0.15
0.15 – 0.15
+3.6% YoY
0.20
0.20 – 0.20
+37.9% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-22 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-21 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-20 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-19 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-18 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-15 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-14 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-13 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-12 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-11 B- 3/5 1/5 3/5 4/5 2/5 1/5 4/5
2026-05-08 C+ 2/5 1/5 2/5 3/5 2/5 1/5 4/5
2026-05-07 C+ 2/5 1/5 2/5 3/5 2/5 1/5 4/5
2026-05-06 C+ 2/5 1/5 2/5 3/5 2/5 1/5 4/5
2026-05-05 B- 2/5 1/5 2/5 3/5 2/5 2/5 4/5
2026-05-04 B- 2/5 1/5 2/5 3/5 2/5 2/5 4/5
2026-04-30 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-29 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-28 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-27 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-24 B- 2/5 1/5 2/5 4/5 1/5 2/5 4/5
2026-04-23 C+ 2/5 1/5 2/5 4/5 1/5 1/5 4/5
2026-04-22 C+ 2/5 1/5 2/5 4/5 1/5 1/5 4/5
2026-04-21 C+ 2/5 1/5 2/5 4/5 1/5 1/5 4/5
2026-04-20 C+ 2/5 1/5 2/5 4/5 1/5 1/5 4/5
2026-04-17 C+ 2/5 1/5 2/5 4/5 1/5 1/5 4/5
2026-04-16 C+ 2/5 1/5 2/5 4/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
30.87M
OE per share TTM
0.39
Owner's Yield
13.89%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
35.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 2 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Dimensional - International Small Cap Value ETF DISV 0.00% 2.7K 0.42%
2 Dimensional - International Core Equity 2 ETF DFIC 0.00% 61.85 0.22%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
4.3K
Shares Outstanding
81.41M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ignasi Biosca Reig Chief Executive Officer & Executive Director 445.0K male
Estefanía Ruiz Group Chief Accountant & Controller — female
Inaki Frias Inchausti Non-Director Secretary — male
Inma Santa-Pau Director of Communication & Investor Relations — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic